Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...
Prosper Junior Bakiny has positions in Eli Lilly and Viking Therapeutics. The Motley Fool recommends Viking Therapeutics. The ...
Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...
A larger pharma company may decide it's worth taking Viking's promising drug candidate through phase 3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback